600285 羚锐制药
2023/09 - 九个月
人民幣(K¥)
与去年同期
比较
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
营业总收入2,506,78110.09%3,001,8622,693,5112,331,5772,157,052
减:营业总成本1,988,2164.18%2,584,4172,296,6341,997,8011,821,377
    其中:营业成本636,0434.39%832,114692,993538,403489,927
               财务费用(24,457)45.20%(26,588)(10,334)(15,290)(2,104)
               资产减值损失(196)46.02%(171)(8,775)(32,028)(4,434)
公允价值变动收益59-744.16%5,92646(52)(8,246)
投资收益10,777-82.69%58,65530,55541,208(1,748)
    其中:对联营企业和合营企业的投资收益(227)-100.45%43,35018,52233,230(5,733)
营业利润539,09718.03%517,121435,012367,092341,447
利润总额537,87717.77%517,035413,351364,201341,284
减:所得税费用71,69139.79%51,70350,85239,81948,139
净利润466,18614.99%465,331362,500324,382293,145
减:非控股权益4-94.42%0957(1,107)(1,292)
股东净利润466,18215.01%465,331361,543325,489294,437

市场价值指针
每股收益 (元) *0.83013.08%0.8360.6500.5730.512
每股派息 (元) *----0.6000.5000.4000.300
每股净资产 (元) *4.78010.91%4.4954.0144.0733.892
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容